Digger Pharmaceuticals announced that the company plans to sign a “license agreement” with AstraZeneca to grant it the exclusive right to develop and commercialize Schwarzer® around the world. The company will receive a down payment of 600 million US dollars, clinical development milestones of up to 400 million US dollars, sales milestone payments of up to 500 million US dollars, and royalties based on sales. AstraZeneca is an associated corporation, and this transaction constitutes a related transaction. The final entry into force of the agreement is subject to approval by the company's shareholders' meeting and relevant agencies.

Digger Pharmaceuticals announced that the company plans to sign a “license agreement” with AstraZeneca to grant it the exclusive right to develop and commercialize Schwarzer® around the world. The company will receive a down payment of 600 million US dollars, clinical development milestones of up to 400 million US dollars, sales milestone payments of up to 500 million US dollars, and royalties based on sales. AstraZeneca is an associated corporation, and this transaction constitutes a related transaction. The final entry into force of the agreement is subject to approval by the company's shareholders' meeting and relevant agencies.